Veru anticipates filing a new IND for sabizabulin to address inflammation in atherosclerotic cardiovascular disease, with Phase 2 studies using coronary CT angiography as the primary endpoint. IND ...

Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor ...

Inc. reported its Q1 FY2025 earnings, revealing a net loss per share of $0.06, which was better than the projected loss of $0.08. The company's revenue reached $3.2 million, surpassing the forecast of ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Ducommun Incorporated (NYSE: DCO) ("Ducommun” or the "Company”) today announced that it plans to release the Company's 2024 fourth quarter financial results on February 27, 2025, prior to the stock ...

Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

In the Ministry of Labour, Employment, Social Affairs and Veteran Affairs, the arrest of several officials of the ministry is ...

Veru Inc (NASDAQ:VERU) is set to release its Q1 2025 earnings on Feb 13, 2025. The consensus estimate for Q1 2025 revenue is ...

Bedfordshire has one of the highest homicide rates in England and Wales, new figures show. Office for National Statistics figures show Bedfordshire Police recorded nine homicide victims in the year to ...